Study in Progress

Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets: A Symposium

Statement of Task

The U.S. National Academies of Sciences, Engineering, and Medicine (the National Academies) and the Russian Academy of Sciences will organize a joint symposium to discuss opportunities and approaches for supplying molybdenum-99 (Mo-99) and associated medical isotopes (iodine-131 and xenon-133) to global markets. The symposium will address the following topics:

-- Trends in global demand and supply for Mo-99 and associated medical isotopes.
-- Prospects and approaches for developing new global supplies of Mo-99 and associated medical isotopes.
-- Technical, regulatory, economic, and policy considerations for producing Mo-99 and associated medical isotopes for global markets using uranium-fission and other processes.

The symposium presentations and discussions will be summarized in a National Academies proceedings that will be issued in English and Russian.

Photos: Download 40 photos from the event as a single zipped file (126MB)

 

Program: Download Symposium Program

 

Presentations

(click on presenter's name to download a PDF of their presentation slides)


Day 1


Welcome
Meera Venkatesh, International Atomic Energy Agency
Christophe Xerri, International Atomic Energy Agency

 

Statement from the US and Russian Academies
Stepan Kalmykov, co-chair, Russian Academy of Sciences (on behalf of the symposium organizing committees)

 

 

Plenary Session


Mo-99 production: past, present, and future
Hedvig Hricak, co-chair, U.S. National Academies (on behalf of the symposium organizing committees)

 

Russia’s role in global molybdenum-99 supply
Alexey Vakulenko, JSC V/O IZOTOP, Russian Federation

 

Establishing and expanding nuclear medicine programs
Rodolfo Nunez-Miller, International Atomic Energy Agency
Wolfgang Weber, Memorial Sloan Kettering, United States

 

 

Molybdenum-99 Supply Reliability: Session 1


Organisation for Economic Co-operation and Development-Nuclear Energy Agency’s principles to address molybdneum-99 supply reliability and the organization’s global market demand and production capacity projections
Kath Smith, High-level Group on the Security of Supply of Medical Radioisotopes

 

The European Commission’s efforts to evaluate the supply of medical radioisotopes
Margarida Goulart, European Commission

 

Reactor schedule coordination for molybdenum-99 supply reliability
Bernard Ponsard, AIPES Reactors & Isotopes Working Group

 

Investments in AREVA’s target production facility to improve long term sustainable security of molybdneum-99 supply
Yann Guinard, AREVA, France

 

 

Molybdenum-99 Supply: Session 2 (part 1)


Existing global suppliers: current production and future plans
Roy Brown, Curium
Michael Druce, ANSTO, Australia
Gavin Ball, NTP, South Africa
Jean-Michel Vanderhofstadt, IRE, Belgium

 

 

Molybdenum-99 Supply: Session 2 (part 2)


New projects for regional or global molybdenum-99 supply
James Harvey, NorthStar, United States
Katrina Pitas, SHINE, United States
Carolyn Haass, Northwest Medical Isotopes, LLC, United States
Carmen Bigles, Coquí Radio Pharmaceuticals, United States
Matthew Lish, Flibe Energy, United States
Hermen van der Lugt, PALLAS Reactor, Netherlands
Oleg Kononov, Karpov Scientific Research Institute of Physics and Chemistry, Russian Federation
Ken Buckley, TRIUMF, Canada
Kennedy Mang’era, Canadian Isotope Innovations Corp.
Jin Du, China Isotope & Radiation Corporation
Anupam Mathur, Department of Atomic Energy, India
Ul-Jae Park, Korea Atomic Energy Research Institute
Pablo Cristini, National Atomic Energy Commission, Argentina
Mostafa Abd Elaal, Egyptian Atomic Energy Authority

 

 

Day 2 


Technical Considerations : Session 3


Conversion to low enriched uranium-based molybdenum-99 production
Jean-Michel Vanderhofstadt, IRE, Belgium
Roy Brown, Curium
Gavin Ball, NTP, South Africa
Vladimir Risovaniy, Rosatom, Russian Federation

 

Production expansion
Michael Druce, ANSTO, Australia

 

Prospects for the use of activation of molybdenum for the production of technetium-99m generators
Victor Skuridin, Tomsk Polytechnic University, Russian Federation

 

High-density low enriched uranium targets production
Bertrand Stepnik, AREVA, France
Kinam Kim, Korea Atomic Energy Research Institute

 

 

Regulatory Considerations: Session 4


European Medicines Agency’s regulatory considerations
Brendan Cuddy, European Medicines Agency

 

Perspectives from Tc-99m generator manufacturers
Ira Goldman, Lantheus Medical Imaging, United States
Roy Brown, Curium, Netherlands

 

Perspectives from a nuclear pharmacy
David Pellicciarini, Cardinal Health, United States

 

 

Economic Considerations: Session 5

Molybdenum-99 supply economics
Jan Willem Velthuijsen, PwC Europe

 

Low enriched uranium-based molybdenum-99 production
Gavin Ball, NTP 
Michael Druce, ANSTO

 

 

Chemical Processing and Waste Management: Session 6


Chemical processing and waste management following neutron activation
Engeniy Nesterov, Tomsk Polytechnic University, Russian Federation

 

Development of a novel dry chemical uranium molybdenum separation: Research for a future efficient Mo-99 extraction process
Riane Stene, FRM-II, Germany

 

Waste management in HEU versus LEU-based molybdenum-99 production
Jean-Michel Vanderhofstadt, IRE, Belgium

 

Synroc Technology for the Management of molybdenum-99 Waste
Bruce Begg, ANSTO, Australia

 

Recycling processed LEU for reuse as target material
Carolyn Haass, Northwest Medical Isotopes, LLC, United States